Latest Trials
| EudraCT Number: 2004-000903-17 | Sponsor Protocol Number: CN138-166 | Start Date: 2005-02-23 | ||||||
| Sponsor Name: Bristol-Myers Squibb International Corporation | ||||||||
| Full Title: A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients | ||||||||
| Medical condition: Schizophrenia | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||
| Trial protocol: BE (Completed) | ||||||||
| Trial results: View results | ||||||||
| EudraCT Number: 2004-004308-19 | Sponsor Protocol Number: ITOFD04-04 | Start Date: 2005-02-23 | ||||||
| Sponsor Name: AXCAN PHARMA Inc. | ||||||||
| Full Title: A multicentre, open-label study to evaluate the long-term safety and efficacy of itopride HCl in patients suffering from functional dyspepsia | ||||||||
| Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia | ||||||||
|
||||||||
| Population Age: Adults | Gender: Male, Female | |||||||
| Trial protocol: DE (Prematurely Ended) BE (Completed) | ||||||||
| Trial results: View results | ||||||||
| EudraCT Number: 2004-002686-21 | Sponsor Protocol Number: Bosentan1 | Start Date: 2005-02-22 | ||||||
| Sponsor Name: Dept of Dermatology | ||||||||
| Full Title: Efficacy of Endothelin 1 receptor antagonist Bosentan in secondary Raynauds Syndrom | ||||||||
| Medical condition: secondary Raynauds Syndrome | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||
| Trial protocol: AT (Completed) | ||||||||
| Trial results: (No results available) | ||||||||
| EudraCT Number: 2004-002787-15 | Sponsor Protocol Number: CLL8/ML17102 | Start Date: 2005-02-22 | |||||||||||
| Sponsor Name: F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FC-R) versus chemotherapy with Fludarabine and Cyclophosphamide (FC) alone in patients with previous... | |||||||||||||
| Medical condition: With an annual incidence of 3/100,000 chronic lymphocytic leukaemia is the most common leukaemia in western countries. Pathogenetically and cytomorphologically CLL belongs to the group of low-grade... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Ongoing) DK (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-001756-36 | Sponsor Protocol Number: MO18264 | Start Date: 2005-02-22 | |||||||||||
| Sponsor Name: LYSA (The Lymphoma Study Association) | |||||||||||||
| Full Title: A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (Mabthéra® ) after induction of res... | |||||||||||||
| Medical condition: Follicular lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) FI (Completed) CZ (Completed) PT (Completed) GB (Completed) ES (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-000506-52 | Sponsor Protocol Number: SE-866/44 | Start Date: 2005-02-22 | |||||||||||
| Sponsor Name: Sankyo Pharma GmbH | |||||||||||||
| Full Title: Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study | |||||||||||||
| Medical condition: NIDDM (non insulin dependent diabetes mellitus) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) CZ (Completed) SK (Completed) EE (Completed) LV (Completed) IT (Completed) GB (Completed) BE (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-000933-12 | Sponsor Protocol Number: AX-CL-10 | Start Date: 2005-02-22 | ||||||
| Sponsor Name: Axonyx Inc | ||||||||
| Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease | ||||||||
| Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu... | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||
| Trial protocol: ES (Ongoing) | ||||||||
| Trial results: (No results available) | ||||||||
| EudraCT Number: 2004-002934-20 | Sponsor Protocol Number: M04-691 | Start Date: 2005-02-22 | ||||||
| Sponsor Name: Abbott GmbH & Co. KG | ||||||||
| Full Title: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe C... | ||||||||
| Medical condition: Crohn's Disease | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||
| Trial protocol: BE (Completed) | ||||||||
| Trial results: View results | ||||||||
| EudraCT Number: 2004-002030-19 | Sponsor Protocol Number: ABCSG-24 | Start Date: 2005-02-22 | ||||||
| Sponsor Name: AUSTRIAN BREAST CANCER STUDY GROUP | ||||||||
| Full Title: A randomized phase III study comparing epirubicin, docetaxel and capecitabine + G-CSF to epirubicin and docetaxel + G-CSF as neoadjuvant treatment for early HER-2 negative breast cancer and compari... | ||||||||
| Medical condition: early HER-2 breast cancer | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||
| Trial protocol: AT (Completed) | ||||||||
| Trial results: (No results available) | ||||||||
| EudraCT Number: 2004-001749-13 | Sponsor Protocol Number: P04071 | Start Date: 2005-02-22 | ||||||
| Sponsor Name: AESCA Pharma GesmbH | ||||||||
| Full Title: Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy alone | ||||||||
| Medical condition: Patients with non small cell lung cancer (NSCLC) have a high risk of developing brain metastasis, up to 40% as evaluated in autopsy studies. These patients are often heavily symptomatic and their l... | ||||||||
|
||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||
| Trial protocol: AT (Prematurely Ended) | ||||||||
| Trial results: View results | ||||||||